Isothermal Nucleic Acid Amplification Technology (INAAT) Market worth $1,651 Million by 2018, According to a New Study on ASDReports

Tuesday 10 June 2014, Amsterdam

The “Isothermal Nucleic Acid Amplification Technology (INAAT) Market by Application (Infectious Diseases, Blood Screening, Research), Products (Instruments, Reagents), End-User (Hospital, Reference Laboratories, Other) - Global Forecast to 2018” provides a detail overview of major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global Isothermal Nucleic Acid Amplification technology market along with the estimates and forecast of revenue and share analysis.

The global isothermal nucleic acid amplification technology (INAAT) market is poised to reach $1,651 million by 2018 at a CAGR of 13.5% during the forecast period. The increasing demand for enhanced molecular testing using INAAT as well as rising incidence of infectious diseases is driving market growth over the conventional thermal polymerase chain reaction (PCR) technology.

In addition to increasing population suffering from infectious disease and cancer, promise for less expensive molecular testing using INAAT, better throughput in gene amplification, and advent of novel technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA) play pivotal role in propelling market momentum. On the other hand, inadequate advanced infrastructure and higher dependency on convention method (PCR technology) restrict market growth globally.

Amongst various applications of INAAT, prognosis and diagnosis of infectious disease allows a huge scope for market penetration of novel isothermal technologies such as Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence Based Amplification (NASBA) and Helicase Dependent Amplification (HDA) among others. Infectious disease application market, especially sexually transmitted disease (STD) and hepatitis A & B, is expected to witness a double digit growth rate during the forecast period. Moreover, blood screening application is also expected to be a significant revenue pocket of INAAT due to increasing practice of mandatory testing of donated blood at blood donation unit to ensure the quality of blood sample.

End-users analysis identified reference laboratory as a potential segment ensuring a rapid growth of various isothermal amplification technologies in different complex molecular testing; whereas, technology roadmap analysis expected a rapid adoption of single miniaturized devices in the global molecular diagnostics industry.

Various private investors, venture capital firms (Bill & Melinda Gates Foundation, Wellcome Trust), and public funding bodies (the National Institutes of Health and the Centers for Disease Control and Prevention) were found to be significant investors encouraging speedy penetration of advanced isothermal technologies. On the other hand, demand side analysis considered portability and affordability the major factors contributing the competitive edge to isothermal technologies as compared to convention PCR technology.

Increasing prevalence rate of infectious diseases and significant adoption of novel technologies are expected to ensure a double digit growth in emerging nations, especially in India, China, South Africa, Singapore, and Middle East. However, INAAT in developed countries is also expected to witness a steady grow in the diagnosis of various infectious diseases such as healthcare-associated infections and sexually transmitted diseases.

The key players in the market include Alere, Inc. (U.S.), Becton, Dickinson & Company (U.S.), BioHelix (U.S.), bioMerieux (France), Hologic Gene-Probe (U.S.), and QIAGEN (The Netherlands).